• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is awarded a research grant from “Regione Toscana”

Dec 23, 2015 | 2015, Press Releases, Scientific

Philogen is awarded a research grant from “Regione Toscana” for a project focusing on the development of new strategies of Factor V purification for patients in need thereof. POSTER PROGETTO FV-OD

Dario Neri, the co-founder and Chairman of the Scientific Advisory Board presented at the 11th Annual European Antibody Congress in Basel, Switzerland, 9th-11th November.

Nov 9, 2015 | 2015, Past Events

Dario Neri, the co-founder and Chairman of the Scientific Advisory Board presented at the 11th Annual European Antibody Congress in Basel, Switzerland, 9th-11th November. The title of the talk was “Armed Antibodies for the treatment of Cancer and of Chronic...

Dario Neri, the co-founder and chairman of the scientific advisory board of Philogen will deliver the keynote speech at the First Boston Symposium of Encoded Library Platforms in Boston

Nov 6, 2015 | 2015, Past Events

Dario Neri, the co-founder and chairman of the scientific advisory board of Philogen will deliver the keynote speech at the First Boston Symposium of Encoded Library Platforms in Boston, 6th November. The title of his presentation will be “Single-Pharmacophore and...

Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim

Oct 12, 2015 | 2015, Press Releases, Scientific

Philogen is pleased to announce that it has signed a collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia. Siena (Italy), October 12th. (see full Press Release).

Philogen. Data from Phase Ib clinical trial of Dekavil in rheumatoid arthritis

Sep 27, 2015 | 2015, Past Events

Philogen. Data from Phase Ib clinical trial of Dekavil in rheumatoid arthritis were presented at the 4th Israel-Italy Meeting of Autoimmunity and Autoinflammation: Cutting Edge. Siena (Italy), September 27th-28th.

Philogen attended BIO in Philadelphia, PA (USA), 15th-19th June, 2015.

Jun 12, 2015 | 2015, Past Events

« Older Entries

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philogen is pleased to invite you to an upcoming webinar on November 20, 2025, at 15:00 GMT | 16:00 CET.
  • The Board of Directors approves the financial position for the third quarter of 2025
  • Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al terzo trimestre 2025
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it